Srividya Kotapati
Overview
Explore the profile of Srividya Kotapati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Potluri R, Ranjan S, Bhandari H, Johnson H, Moshyk A, Kotapati S
Exp Hematol Oncol
. 2019 Jul;
8:14.
PMID: 31312536
Background: Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant breakthroughs in the treatment of...
12.
Middleton M, Atkins M, Amos K, Wang P, Kotapati S, Sabater J, et al.
BMC Cancer
. 2017 Oct;
17(1):689.
PMID: 29041898
Background: No studies have measured preference-based utility weights for specific toxicities and outcomes associated with approved and investigational adjuvant treatments for patients with resected high-risk melanoma. Methods: A cross-sectional study...
13.
Suciu S, Eggermont A, Lorigan P, Kirkwood J, Markovic S, Garbe C, et al.
J Natl Cancer Inst
. 2017 Sep;
110(1).
PMID: 28922786
Background: We assessed whether relapse-free survival (RFS; time until recurrence/death) is a valid surrogate for overall survival (OS) among resected stage II-III melanoma patients through a meta-analysis of randomized controlled...
14.
Schadendorf D, Larkin J, Wolchok J, Hodi F, Chiarion-Sileni V, Gonzalez R, et al.
Eur J Cancer
. 2017 Jun;
82:80-91.
PMID: 28651159
Background: Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy...
15.
Coens C, Suciu S, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, et al.
Lancet Oncol
. 2017 Feb;
18(3):393-403.
PMID: 28162999
Background: The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group...
16.
Karweit J, Kotapati S, Wagner S, Shaw J, Wolfe S, Abernethy A
Am J Manag Care
. 2017 Feb;
23(1):54-61.
PMID: 28141932
Objectives: With the introduction of more effective anticancer agents that prolong survival, there is a need for new methods to define the clinical value of treatments. The objective of this...
17.
Middleton M, Dalle S, Claveau J, Mut P, Hallmeyer S, Plantin P, et al.
Cancer Med
. 2016 Apr;
5(7):1436-43.
PMID: 27118102
The therapeutic landscape for advanced melanoma has recently been transformed by several novel agents (immune checkpoint inhibitors and molecular-targeted agents). The prospective, multi-site, observational study IMAGE (ipilimumab: management of advanced...
18.
Zhang Y, Le T, Shaw J, Kotapati S
Clinicoecon Outcomes Res
. 2015 Aug;
7:397-407.
PMID: 26229494
Background: This study examines real-world drug utilization patterns, health care resource use, and costs among patients receiving adjuvant treatment with IFN versus patients receiving no treatment ("observation") for malignant melanoma...
19.
Barzey V, Atkins M, Garrison L, Asukai Y, Kotapati S, Penrod J
J Med Econ
. 2012 Oct;
16(2):202-12.
PMID: 23057750
Objective: To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. Methods: The analysis was based on a US payer perspective...
20.
Dequen P, Lorigan P, Jansen J, van Baardewijk M, Ouwens M, Kotapati S
Oncologist
. 2012 Oct;
17(11):1376-85.
PMID: 23024154
Objective: To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients. Methods: A systematic...